Bilaketaren emaitzak - Hans Ericsson

The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses nork Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker

Connect to this object online.

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction nork Karin Nelander, Maria Lagerstrom‐Fermer, Carl Amilon, Erik Michaëlsson, Maria Heijer, Magnus Kjaer, Muir Russell, David Han, Eva‐Lotte Lindstedt, Carl Whatling, Li‐Ming Gan, Hans Ericsson

Connect to this object online.

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study nork Andrew Whittaker, Åsa M. Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik, Hans Ericsson

Connect to this object online.

Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants nork Xue‐Qing Li, Bo Lindmark, Carl Amilon, Kristin Samuelsson, Lars Weidolf, Karin Nelander, Jane Knöchel, Maria Heijer, Ryan A. Bragg, Malin Gränfors, Eva‐Lotte Lindstedt, Sharan Sidhu, Pavlo Garkaviy, Hans Ericsson

Connect to this object online.